COVID-19
+2
Safety and Immunogenicity of COVID-19 Vaccine Booster in Patients With Liver Diseases
Sponsored by Huashan Hospital
About this trial
Last updated 4 years ago
Study ID
CLD-BOOST
Status
Recruiting
Type
Observational
Placebo
No
Accepting
18+ Years
All
Not accepting
Healthy Volunteers
Trial Timing
Ended 3 years ago
What is this trial about?
Previous studies should that patients with chronic liver diseases, cirrhosis, hepatocellular
carcinoma and post-liver-trasplant status had lower immunological response to SARS-CoV-2
vaccines than healthy population. Along with the waning of antibody and emerging SARS-CoV-2
variants, a third dose SARS-CoV-2 booster vaccination is now considered as an effective
strategy. Previous studies showed good safety and immunogenicity of the SARS-CoV-2 booster
vaccination in healthy population. However, the relevant information in patients with liver
diseases need further research. This study (NMCID-CHESS 2201) aimed to investigate the safety
and immunogenicity of the SARS-CoV-2 booster vaccination in population with chronic liver
diseases
What are the participation requirements?
Inclusion Criteria
- Previously vaccinated with two doses of SARS-CoV-2 vaccines and planning to get booster vaccination.
- Clinically or pathologically diagnosed with pre-existing liver disease, including: chronic liver diseases, cirrhosis, liver cancer, liver transplant subjects, etc.
- Understanding and willing to comply with the study procedures and provides written informed consent.
Exclusion Criteria
- Pregnancy or lactation.
- Active or known history of SARS-CoV-2 infection.
- Diseases causing immunosuppressive or immunodeficient status or autoimmune diseases.
- A history of discontinuing anti-HBV agents in recent three months.
Locations
Location
Status
Recruiting